Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Engineered Human Stem Cell Therapy,Ozogamicin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Vor Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases
Details : This collaboration strengthens Akron’s portfolio of off-the-shelf gene editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene modified cell therapies including VOR33.
Brand Name : VOR33
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : Engineered Human Stem Cell Therapy,Ozogamicin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Vor Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Virally inactivated human AB serum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Octapharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Partnership Aims to Enhance Safety of Human Serum from Viruses. Under the agreement, Akron Biotech will produce Human AB Serum converted from Octaplas®, which is Octapharma’s pooled, solvent/detergent treated human plasma product.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 20, 2021
Lead Product(s) : Virally inactivated human AB serum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Octapharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Agreement
Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-Beta for COVID-19 Treatment
Details : Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgen’s formulation.
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 19, 2020
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?